Leukocyte attraction through the CCR5 receptor controls progress from insulitis to diabetes in nonobese diabetic mice

被引:78
作者
Carvalho-Pinto, C
García, MI
Gómez, L
Ballesteros, A
Zaballos, A
Flores, JM
Mellado, M
Rodríguez-Frade, JM
Balomenos, D
Martinez, C
机构
[1] Univ Autonoma Madrid, CSIC, Dept Immunol & Oncol, Ctr Nacl Biotecnol, E-28049 Madrid, Spain
[2] Univ Complutense Madrid, Fac Vet, Dept Patol Anim 2, Madrid, Spain
关键词
chemokine receptor; autoimmune disease; diabetes; NOD mice; CCR5;
D O I
10.1002/eji.200324285
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lymphocyte infiltration to pancreatic islets is associated to chemoattraction, as are other inflammatory autoimmune processes. We examined whether development of insulitis and diabetes depends on chemoattraction of lymphocytes via the CCR5 chemokine receptor. In non-obese diabetic (NOD) mice, a substantial fraction of peripheral T cells and virtually all B cells expressed high CCR5 levels. CCR5 expression characterized the effector T cell phenotype, suggesting their potential involvement in disease development. In view of these findings and the CCL5 (RANTES, the CCR5 ligand) expression by pancreatic islets, we treated NOD mice with a neutralizing anti-CCR5 antibody. This did not influence peri-insulitis advancement, but inhibited beta-cell destruction and diabetes. These data demonstrate a role of CCR5-dependent chemoattraction in insulitis progression to islet destruction, suggesting the potential value of therapeutic intervention by CCR5 targeting.
引用
收藏
页码:548 / 557
页数:10
相关论文
共 30 条
  • [1] Chemokines in islet allograft rejection
    Abdi, R
    Means, TK
    Luster, AD
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2003, 19 (03) : 186 - 190
  • [2] The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection
    Abdi, R
    Smith, RN
    Makhlouf, L
    Najafian, N
    Luster, AD
    Auchincloss, H
    Sayegh, MH
    [J]. DIABETES, 2002, 51 (08) : 2489 - 2495
  • [3] Checkpoints in the progression of autoimmune disease: Lessons from diabetes models
    Andre, I
    Gonzalez, A
    Wang, B
    Katz, J
    Benoist, C
    Mathis, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (06) : 2260 - 2263
  • [4] André-Schmutz I, 1999, EUR J IMMUNOL, V29, P245, DOI 10.1002/(SICI)1521-4141(199901)29:01<245::AID-IMMU245>3.3.CO
  • [5] 2-F
  • [6] INSULIN-DEPENDENT DIABETES-MELLITUS AS AN AUTOIMMUNE-DISEASE
    BACH, JF
    [J]. ENDOCRINE REVIEWS, 1994, 15 (04) : 516 - 542
  • [7] The NOD mouse - Introduction
    Bach, JF
    Mathis, D
    [J]. RESEARCH IN IMMUNOLOGY, 1997, 148 (05): : 285 - 286
  • [8] Tolerance to islet autoantigens in type 1 diabetes
    Bach, JF
    Chatenoud, L
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 : 131 - 161
  • [9] CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions
    Balashov, KE
    Rottman, JB
    Weiner, HL
    Hancock, WW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) : 6873 - 6878
  • [10] Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice
    Balomenos, D
    Rumold, R
    Theofilopoulos, AN
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) : 364 - 371